Under a tenth of individuals eligible to benefit from weight-loss injections including Wegovy are able to get them, states the WHO as it releases its first guidance on the drugs.
Considering over a billion people worldwide now living with obesity, it is advocating for broader and more equitable availability to these injectable treatments.
According to forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"Our new guidance acknowledges that obesity is a lifelong illness that can be addressed with holistic and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are key obstacles to universal availability to the injections that can assist patients in reducing substantial body mass, explains the organization.
Weight-Loss Drug Scarcity
Even under the current most favorable outlook, the production of such drugs would only suffice for approximately 100 million people – fewer than 10% of eligible patients, according to the WHO.
The guideline encourages nations and manufacturers to widen access, by measures such as licensing agreements.
The intellectual property rights on the active ingredient – the core component of a leading brand – is set to lapse in a number of countries in 2026.
The Way Weight-Loss Drugs Operate
These medications replicate a biological compound to slow digestion, curb appetite and increase feelings of fullness so users reduce food intake.
Individuals typically start to lose weight in the initial weeks of starting on the once-weekly jabs.
Studies points to users may put most of the weight back on after a year of halting the treatment, because their typical hunger resume.
Being overweight or obese increases your chance for developing diseases, such as type 2 diabetes, heart disease, stroke, and some cancers.
Excess weight affects individuals in all nations and was associated with millions of fatalities worldwide in 2024, per the health agency.
